Welcome to Mesothelioma.net - Turning Hope and Faith into Action.

Immunotherapy Vaccine/Surgery Combination Cause for Hope

In a development that has been described as “promising”, researchers from the University of Pennsylvania’s Abramson Cancer Center have announced that by performing surgery to debulk a mesothelioma tumor, vaccine-based immunotherapy offers a viable, positive option for mesothelioma patients.

There has been a tremendous amount of attention paid to the future of immunotherapy in the treatment of many cancers, and scientists have developed vaccines that have proven effective in some cases, but that has not been the case for those suffering from malignant pleural mesothelioma. According to thoracic surgeon and director of the Thoracic Surgery Research Laboratory at Penn Medicine Dr. Sunil Singhal, “What we’ve seen so far is that the vaccine by itself – with advanced disease – doesn’t seem to work very well.” The problem is that tumors that are well established – which is often the case with mesothelioma tumors – develop the ability to suppress the immune system, and thus far researchers have been unable to breach this barrier.

Malignant mesothelioma is a disease with a long latency period, and by the time it is diagnosed the tumors are often very well established. But the Penn group has found that by using a vaccine that is a modified version of Listeria, and using it in combination with surgery to remove the bulk of the tumor, there is a much better chance of seeing positive results. “If the vaccine can rev up or amplify the immune system and we take out the tumors, it can attack what’s left over and finish the job. There is real potential here.”

According to the report published in the journal Immunology Letters, the scientists first tested the effectiveness of the vaccine of tumor growth on immature tumors that they created themselves, as well as on tumors that were well established. They found that the vaccine was not effective in tumors that were mature, or when administered at the same time as tumor reduction surgery. However, they found that “Surgical acytoreduction of established tumors restored the anti tumor potency of the therapeutic vaccine, with significantly reduced tumor burden at post-operative day 18. We found that surgery reduced MDSCs to levels comparable to those in tumor-naive mice. This study demonstrates that cytoreduction surgery restores the efficacy of cancer vaccines for malignant pleural mesothelioma by reducing tumor-related immunosuppression that impairs immunotherapy.”

Terri Oppenheimer

Terri Oppenheimer is an experienced blog writer, editor, and proofreader. She graduated from the College of William and Mary with a degree in English. She specializes in providing content for websites and finds tremendous enjoyment in the things she learns while doing her research. Her specific areas of expertise include health, medical research, and law.

Get Your FREE Resources Sent Overnight

  • New treatment options
  • Veterans benefits & claims
  • $30 Billion asbestos trust fund information

– Or Call –

Site Navigation

Where can I

Get Additional Help?

For over 15 years, we’ve provided the best FREE resources to mesothelioma patients and loved ones. Our resources include information on the leading treatment options and best doctors in your area; lessons learned from survivors; claims and benefits specifically for Veterans; and how to access your share of billions of dollars in trust fund money.

Get Your FREE Resources Sent Overnight

  • New Treatment Options
  • Veteran's Benefits & Claims
  • $30 Billion Asbestos Trust Fund Information

– Or Call –

We are here to help you


If you've been diagnosed with asbestos-related cancer, contact us at 1-800-692-8608 to find out if you are eligible to receive compensation. You can also fill out the form above to receive FREE information.

Quick Compensation - $30 Billion Trusts
$30 Billion Asbestos Trusts
Get Started